PHASTAR Joins Oncology Development Programme (ODP2) to Accelerate Development of Novel Cancer Innovations

 London, UK and Durham, NC – 08 December, 2022 –  Phastar, a global specialist biometrics contract research organization (CRO), has joined Lean Life Science’s Oncology Development Programme (ODP2). The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.

In collaboration with top global pharma companies, Cancer Research UK’s Cancer Research Horizons, Manchester Cancer Research Centre (MCRC) and more than 20 specialist CROs, ODP2 aims to identify, de-risk and catalyse commercially viable UK-based innovations to improve diagnosis and treatment of cancer and accelerate the translation of emerging cancer research for patient benefit.

Phastar will be offering support from its biometrics experts, including statisticians, data scientists, data managers and programmers as part of the scheme. Its commitment to ODP2 mirrors its existing Phastar CARES programme – a comprehensive, corporate Environmental, Social, and Governance (ESG) strategy which offers pro bono support to charities.

Continue Reading

PHASTAR Launches Pro-Bono Scheme for Charities

New pro-bono scheme allows charities to access PHASTAR’s biometrics experts at no cost

London, UK and Durham, NC - November 5, 2022 - PHASTAR, a global specialist biometrics contract research organization (CRO), has announced the launch of a pro-bono scheme to give charities access to its volunteer statisticians, data scientists, data managers and programmers at no cost.

PHASTAR CARES allows third-sector organisations to fulfil their charitable aims by providing biometrics support they may otherwise be unable to afford. The team of experts can advise on data collection, analysis and dissemination.

Andrew MacGarvey, CEO commented: “PHASTAR’s experts are thought leaders who can use the right tools to help charities gain important insight. They are excellent communicators, adept at understanding the needs of the client, and can help charities extract the most value from their data. PHASTAR CARES is a tailor-made service, increasing understanding of data and evidence to aid decision making.”

Continue Reading

Introducing the Centre for Analytical Excellence

The experience across the team at PHASTAR is rich and varied and on average the technical team has over 14 years’ experience, which is a wealth of knowledge that brings huge benefits to our clients. The team are not only experts working with data but also the analytics of that data to deliver value. The wealth of analytical experience is challenging to quantify with expertise ranging from statistical methodology to mathematical modelling to data science.

What is clear however, is that we wanted to make the most of the abundance of talent we have within the company. To provide an environment for individuals to contribute where they have knowledge and to learn where they have interest. This benefits not only our team as they continue to grow and learn, but also our projects and clients as we can strengthen our technical expertise even further.

It is on this basis that the Centre for Analytical Excellence was born, providing a holistic and unified approach to advanced analytics at PHASTAR. There are a few key objectives at the core of this initiative that we believe will enable PHASTAR to maximise the analytical capability we have across the company.

Continue Reading

PHASTAR Names Ping-Chung Chang as Head of China Development and Global Delivery  

 Beijing, China and London, UK, April 20, 2022 – PHASTAR, a global specialist biometrics contract research organization (CRO) offering industry leading data management, data science, statistical consulting, and clinical trial reporting services, today announces that Ping-Chung Chang has joined the company as Head of China Development and Global Delivery. Ping brings deep experience in CRO operations, business excellence, biotech/biopharma, research and development process, and regulatory submissions. Headquartered in PHASTAR’s Beijing office, Ping will be responsible for building China development and delivery into PHASTAR’s global business advantage.  

“We are delighted to have someone with Ping’s expertise join our team to expand our presence in the Asia Pacific region,” said Andrew MacGarvey, Chief Executive Officer, PHASTAR. “Ping’s wealth of experience in this market will help continue to drive our success in our latest phase of growth, enhance our overall global delivery excellence, and realize our full business potential.”

Continue Reading

Image depicting PHASTAR and AstraZeneca as joint winners of the ACDM innovation award

PHASTAR announced as joint winner of ACDM Innovation in Management of Clinical Data Award

London, UK and Durham, NC – 22 September 2021PHASTAR, a global specialist biometrics contract research organization offering industry leading data management, data science, statistical consulting and clinical trial reporting services, was announced as a joint winner of the 2021 Innovation in the Management of Clinical Data Award by the Association for Clinical Data Management (ACDM).

The award was in recognition of the work done by PHASTAR data scientists and data managers to develop a novel AI and rule-based approach for the production of auto-generated queries used to identify potential data issues and inconsistencies in clinical trial data. The PHASTAR team integrated the role of the human expert with intelligent process automation through a targeted approach. They are able to discover hotspots of data quality issues on studies through the application of AI (NLP) approaches to the meta data, identifying problematic forms and variables and are now building labelled data sets to which machine learning methods may be applied.

Continue Reading